Parametric evaluation of methotrimeprazine-midazolam-ketamine and methotrimeprazine-midazolam-ketamine-xylazine combination in dogs.
OBJECTIVE
To evaluate the parameters of dogs anesthetized by different dissociative drugs protocols through continuous intravenous infusion.


METHODS
Thirty healthy dogs of both sexes were assigned randomly to three groups (G1, G2, and G3). G1 was administered with methotrimeprazine as a pre-anesthetic medication, intravenously midazolam-ketamine as bolus for induction and midazolam-ketamine by continuous intravenous infusion for a 60 minute-period of maintenance. G2: the same as for G1. plus an increase in the midazolam dose during maintenance. G3: the same treatment as for G2, plus the addition of xylazine during maintenance. Immediately after induction the anesthetic maintenance started, and measures were taken 15 minutes after pre-medication, at 10 minutes intervals, during maintenance (M0 to M7).


RESULTS
Bradycardia, atrioventricular blockage, bradypnea and hypoxemia were shown in G3. G1 and G2 showed a slight hypotension only.


CONCLUSIONS
There were some advantages by using the continuous intravenous via: no parameters oscillation and reduction in the anesthetic recovery period. The increase in midazolam dose brought about little parametric variations which were greater when xylazine was used, with a consequent hypoxemia, bradyarrhytmia, and decrease in respiratory frequency and minute volume.
Santos
Gustavo José Von Glehn dos
GJ
Faculty of Veterinary Medicine and Zootechny, Laboratory of Veterinary Anesthesiology, Julio de Mesquita Filho University, Botucatu, São Paulo, Brazil.
Hatschbach
Eduardo
E
Mattos Júnior
Ewaldo de
Ed
Massone
Flávio
F
D000762:Anesthesia Recovery Period; D000771:Anesthesia, Intravenous / Q000379:methods / Q000662:veterinary; D019162:Anesthetics, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007649:Ketamine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008728:Methotrimeprazine / Q000008:administration & dosage* / Q000009:adverse effects; D008874:Midazolam / Q000008:administration & dosage* / Q000009:adverse effects; D011229:Preanesthetic Medication / Q000379:methods; D011897:Random Allocation; D013997:Time Factors; D014991:Xylazine / Q000008:administration & dosage* / Q000009:adverse effects
D019162:Anesthetics, Combined; D018686:Anesthetics, Intravenous; D014991:Xylazine; D007649:Ketamine; D008728:Methotrimeprazine; D008874:Midazolam